Hydrogen Gas Therapy Slows ALS Progression and Extends Lifespan in Mice

Authors
Journal
Acta Biomaterialia
Year
DOI
10.1016/j.actbio.2026.07.004
Study Type
Mouse
Outcome
Positive
Peer Reviewed
Yes
Country
China
Health Condition
Amyotrophic Lateral Sclerosis (ALS)
Body System
Nervous System

TL;DR

Sustained hydrogen release from oral Mg₂Si nanosheets slowed disease progression and extended survival in an ALS mouse model.

Key Finding

Oral magnesium-silicon nanosheets that slowly release hydrogen gas delayed ALS progression, improved motor function, and extended lifespan in transgenic mice with the disease.

Summary

Researchers tested a new form of hydrogen therapy in mice with a genetic form of ALS (a disease that damages nerve cells controlling movement). They created special magnesium-silicon particles that release hydrogen gas slowly in the digestive system. In genetically engineered mice with ALS, this treatment slowed disease progression, improved movement, and extended lifespan by reducing harmful molecules called free radicals and calming excessive immune activity in the nervous system.

Practical Takeaway

This is early-stage research in mice only, not humans. While the results are promising for understanding how sustained hydrogen delivery might help ALS, it's far too soon to know if this approach would work in people or be safe for human use. Much more research, including human clinical trials, would be needed before any conclusions could be drawn about practical applications.

Abstract (excerpt)

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive motor neuron degeneration in the brain and spinal cord, with mutant superoxide dismutase 1 (SOD1) induced oxidative stress and neuroinflammation as key pathogenic drivers. Here, we uncover that…

Read the full abstract via DOI